> Co-administration with RITONAVIR, an inhibitor of OATP1B, CYP3A and P -gp, or with ITRACONAZOLE, a strong inhibitor of CYP3A and P -gp, resulted in no clinically meaningful (approximately 10 -20%) increase in exposures of TRASTUZUMAB DERUXTECAN or the released topoisomerase  I inhibitor, DXd. No dose adjustment is required during co -administration of TRASTUZUMAB DERUXTECAN with medicinal products that are inhibitors of CYP3A or OATP1B or P -gp transporters (see s ection 5.2).
